The Brigham and Women's Hospital, Inc.

JoAnn E Manson

Paul M Ridker

Matthew H Liang

The invention involves methods for characterizing an individual's risk profile of developing future diabetes or complications of diabetes by obtaining a level of an inflammatory marker in the individual. Preferred inflammatory markers according to the present invention include C reactive protein and interleukin-6. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future diabetes.

Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes

Methods and compositions are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B , vitamin B , and folic acid. Pharmaceutical formulations combining all the active agents in unit-dose form for once-daily dosing are provided.

Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Growing community of inventors

Beverly, MA, United States of America

JoAnn E Manson